Two Sigma Investments LP boosted its holdings in Luminex Co. (NASDAQ:LMNX) by 182.2% during the 4th quarter, Holdings Channel reports. The firm owned 96,246 shares of the medical instruments supplier’s stock after acquiring an additional 62,136 shares during the period. Two Sigma Investments LP’s holdings in Luminex were worth $1,896,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds have also bought and sold shares of the business. BlackRock Inc. boosted its position in Luminex by 0.6% in the fourth quarter. BlackRock Inc. now owns 6,117,732 shares of the medical instruments supplier’s stock worth $120,518,000 after purchasing an additional 33,557 shares during the last quarter. Renaissance Technologies LLC boosted its position in Luminex by 17.5% in the fourth quarter. Renaissance Technologies LLC now owns 2,246,640 shares of the medical instruments supplier’s stock worth $44,259,000 after purchasing an additional 334,900 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Luminex by 3.5% in the third quarter. Dimensional Fund Advisors LP now owns 1,819,417 shares of the medical instruments supplier’s stock worth $36,989,000 after purchasing an additional 61,437 shares during the last quarter. Neuberger Berman Group LLC boosted its position in Luminex by 9.6% in the third quarter. Neuberger Berman Group LLC now owns 1,015,916 shares of the medical instruments supplier’s stock worth $20,654,000 after purchasing an additional 89,141 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its position in Luminex by 17.3% in the fourth quarter. Acadian Asset Management LLC now owns 874,903 shares of the medical instruments supplier’s stock worth $17,237,000 after purchasing an additional 129,032 shares during the last quarter. 81.39% of the stock is currently owned by institutional investors and hedge funds.
Several analysts have issued reports on the company. BidaskClub upgraded Luminex from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 10th. William Blair restated a “market perform” rating on shares of Luminex in a research note on Tuesday, February 13th. Finally, BTIG Research assumed coverage on Luminex in a research note on Friday, January 5th. They issued a “buy” rating and a $24.00 target price on the stock. Four research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $22.33.
Luminex (NASDAQ:LMNX) last issued its earnings results on Monday, February 12th. The medical instruments supplier reported $0.20 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.09 by $0.11. The firm had revenue of $78.20 million for the quarter, compared to analyst estimates of $77.33 million. Luminex had a return on equity of 8.48% and a net margin of 9.48%. The business’s revenue was up 8.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.11 earnings per share. equities research analysts predict that Luminex Co. will post 0.64 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, April 13th. Shareholders of record on Friday, March 23rd will be paid a $0.06 dividend. The ex-dividend date of this dividend is Thursday, March 22nd. This represents a $0.24 annualized dividend and a dividend yield of 1.14%. Luminex’s payout ratio is presently 26.37%.
TRADEMARK VIOLATION WARNING: “Luminex Co. (LMNX) Shares Bought by Two Sigma Investments LP” was posted by WKRB News and is the property of of WKRB News. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://www.wkrb13.com/2018/04/02/luminex-co-lmnx-shares-bought-by-two-sigma-investments-lp.html.
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.
Want to see what other hedge funds are holding LMNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Luminex Co. (NASDAQ:LMNX).
Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.